How does COVID-19 affect my research?
The University Research Continuity Working Group is assessing the impact of COVID-19 on ANU research. Please refer to the University COVID-19 ethics advice
and check the COVID-19 news page
regularly for updates.
Managing an NLRD
You will remain compliant if:
- The dealing is only conducted within a certified PC1 or PC2 facility (as appropriate for the type of GMO involved)
- The dealing is properly supervised (for example, by the IBC of the Accredited Organisation in which the work is conducted) - and a record of the details of the dealing retained
- Any transport of the GMO is conducted in accordance with the Regulator's Guidelines for the Transport, Storage and Disposal of GMOs; and
- If the dealing involves organisms that may produce disease in humans, the NLRD must be conducted in accordance with the vaccination requirements set out in the Australian Standard AS/NZS 2243:3:2010 2.6.4 (Safety in laboratories Part 3: Microbiological safety and containment).
Unintentional release of a GMO
Unintentional releases should be reported to the OGTR via the Secretary of the IBC and Liaison Officers should make sure this requirement is widely known in their local area. Local procedures for reporting unintentional releases (which include reporting to the Secretary of the IBC) should be included in facility manuals.
Depending on the type of non-compliance, the Regulator has the power to cancel licences, certifications or accreditation of organisations and, in the event of continued non-compliance in terms of possible risks to the health and safety of people or risks to the environment, the Regulator may approach the Director of Public Prosecutions to pursue a prosecution under the legislation which may result in a fine or imprisonment.
The Regulator may undertake routine or unannounced visits to organisations to monitor compliance with the conditions of:
- Licences issued for Licenced Dealings